Eidos Therapeutics Inc (NASDAQ:EIDX) insider Jonathan C. Fox sold 5,000 shares of Eidos Therapeutics stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $45.74, for a total transaction of $228,700.00.
NASDAQ:EIDX traded down $2.95 on Thursday, reaching $45.83. 4,279 shares of the company’s stock were exchanged, compared to its average volume of 147,639. The company has a quick ratio of 20.89, a current ratio of 20.89 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.70 billion, a price-to-earnings ratio of -24.66 and a beta of -0.99. The business has a fifty day moving average of $39.98 and a 200-day moving average of $30.63. Eidos Therapeutics Inc has a 52-week low of $8.89 and a 52-week high of $49.29.
Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.01). As a group, equities analysts anticipate that Eidos Therapeutics Inc will post -1.7 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in EIDX. BNP Paribas Arbitrage SA purchased a new stake in shares of Eidos Therapeutics during the first quarter worth approximately $80,000. Rhumbline Advisers purchased a new stake in shares of Eidos Therapeutics during the first quarter worth approximately $445,000. American International Group Inc. increased its stake in shares of Eidos Therapeutics by 2.3% during the first quarter. American International Group Inc. now owns 245,362 shares of the company’s stock worth $5,754,000 after buying an additional 5,586 shares during the period. Fiduciary Trust Co. purchased a new stake in shares of Eidos Therapeutics during the first quarter worth approximately $211,000. Finally, MetLife Investment Advisors LLC purchased a new stake in shares of Eidos Therapeutics during the first quarter worth approximately $198,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.
Several analysts have commented on the stock. Piper Jaffray Companies assumed coverage on shares of Eidos Therapeutics in a research note on Monday, July 22nd. They set an “overweight” rating and a $55.00 price objective for the company. BMO Capital Markets lifted their price objective on shares of Eidos Therapeutics to $50.00 and gave the company an “outperform” rating in a research note on Monday, July 22nd. BTIG Research set a $56.00 price objective on shares of Eidos Therapeutics and gave the company a “buy” rating in a research note on Friday, September 13th. Finally, Zacks Investment Research raised shares of Eidos Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, July 23rd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $37.57.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Featured Story: What are the benefits of a balanced fund?
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.